Literature DB >> 8262236

Crystallization and preliminary X-ray analysis of leukemia inhibitory factor.

C Betzel1, M Visanji, Z Dauter, R Fourme, W Weber, U Marnitz, T Boone, J Pope, J Miller, N Hawkins.   

Abstract

Leukemia inhibitory factor (LIF) is a polyfunctional molecule with significant and diverse biological activities. LIF is a glycoprotein secreted by a number of different cell types in vitro. It is induced in fibroblasts, lymphocytes, monocytes and astrocytes by various inducers such as serum, TNF, interleukin-IP and EGF. Due to extensive and variable glycosylation the molecular weight can range from 38 to 67 kDA. The biological functions of LIF are mediated through a receptor and a signal transducer, gp130, which is also used by factors like interleukin-6 (IL-6), cilliary neurotropic factor (CNTF), and oncostatin M (OSM). Here, we report the crystallization of the non-glycosylated human-like LIF expressed in E. coli. The present crystals diffract to 2.0 A using synchrotron radiation. They belong to the monoclinic space group C2, and the cell dimensions are a = 61.5 A, b = 45.3 A, c = 77.7 A and beta = 112.3 degrees.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8262236     DOI: 10.1016/0014-5793(93)80810-h

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  2 in total

1.  Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer.

Authors:  Timothy Goggin; Quyen T X Nguyen; Alain Munafo
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 2.  Leukemia Inhibitory Factor: An Important Cytokine in Pathologies and Cancer.

Authors:  Megan M Jorgensen; Pilar de la Puente
Journal:  Biomolecules       Date:  2022-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.